The POTENT II randomised trial: Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction

International Journal of Clinical Practice

Volumn 64, Issue 5, 2010, Pages 594-603

  Gittelman, M ^a   McMahon, C G ^b   Rodriguez Rivera J A ^c   Beneke, M ^d   Ulbrich, E ^e   Ewald, S ^d  

^a South Florida Medical Research   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c SECRETARÍA DE SALUD   (Mexico)

^d BAYER PHARMA AG   (Germany)

^e BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VARDENAFIL;

ADULT; AGED; ARTICLE; AUSTRALIA; BACKACHE; BLOOD PRESSURE; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; ERECTILE DYSFUNCTION; FILM COATING; FLUSHING; HEADACHE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEXICO; MULTICENTER STUDY; MUSCLE SPASM; NECK PAIN; NOSE CONGESTION; PENIS ERECTION; PHARYNGITIS; POPULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; TABLET; THORAX PAIN; TOOTH ABSCESS; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AGED; DOUBLE-BLIND METHOD; ERECTILE DYSFUNCTION; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; SULFONES; TABLETS; TREATMENT OUTCOME; TRIAZINES;

EID: 77949382405     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02358.x     Document Type: Article

References (31)

1. NIH Consensus Conference. Impotence. NIH consensus development panel on impotence. JAMA 1993; 270: 83-90.
2. Mulhall J, King R, Glina S, Hvidsten K. Importance of and satisfaction with sex among men and women worldwide: results of the Global Better Sex Survey. J Sex Med 2008; 5: 788-95.
3. Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004; 20: 607-17.
4. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
5. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 2000; 163: 460-3.
6. Bivalacqua TJ, Usta MF, Champion HC, Kadowitz PJ, Hellstrom WJ. Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease. J Androl 2003; 24: S17-37.
7. Rajasekaran M, Kasyan A, Jain A, Kim SW, Monga M. Altered growth factor expression in the aging penis: the Brown-Norway rat model. J Androl 2002; 23: 393-9.
8. Rajasekaran M, White S, Baquir A, Wilkes N. Rho-kinase inhibition improves erectile function in aging male Brown-Norway rats. J Androl 2005; 26: 182-8.
9. Rizvi K, Hampson JP, Harvey JN. Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Pract 2002; 19: 95-8.
10. Schwarz ER, Rastogi S, Kapur V, Sulemanjee N, Rodriguez JJ. Erectile dysfunction in heart failure patients. J Am Coll Cardiol 2006; 48: 1111-9.
11. Montague DK, Jarow JP, Broderick GA, et al. Chapter 1: the management of erectile dysfunction: an AUA update. J Urol 2005; 174: 230-9.
12. Wespes E, Amar E, Hatzichristou D, et al. EAU Guidelines on erectile dysfunction: an update. Eur Urol 2006; 49: 806-15.
13. Cheng E. Real-life safety and efficacy of vardenafil in the treatment of erectile dysfunction - results from 30,010 U.S. patients. J Sex Med 2007; 4: 432-9.
14. Eardley I, Lee JC, Shabsigh R, et al. Vardenafil improves erectile function in men with erectile dysfunction and associated underlying conditions, irrespective of the use of concomitant medications. J Sex Med 2010; 7: 244-55.
15. Edwards D, Hackett G, Collins O, Curram J. Vardenafil improves sexual function and treatment satisfaction in couples affected by erectile dysfunction (ED): a randomized, double-blind, placebo-controlled trial in PDE5 inhibitor-naive men with ED and their partners. J Sex Med 2006; 3: 1028-36.
16. Fisher WA, Rosen RC, Mollen M, et al. Improving the sexual quality of life of couples affected by erectile dysfunction: a double-blind, randomized, placebo-controlled trial of vardenafil. J Sex Med 2005; 2: 699-708.
17. Giuliano F, Rubio-Aurioles E, Kennelly M, et al. Efficacy and safety of vardenafil in men with erectile dysfunction caused by spinal cord injury. Neurology 2006; 66: 210-6.
18. Hatzichristou D, Montorsi F, Buvat J, Laferriere N, Bandel TJ, Porst H. The efficacy and safety of flexible-dose vardenafil (Levitra ®) in a broad population of European men. Eur Urol 2004; 45: 634-41; discussion 641.
19. Hellstrom WJ, Gittelman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763-71.
20. Porst H, Young JM, Schmidt AC, Buvat J. Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups. Urology 2003; 62: 519-23; discussion 523-4.
21. Ralph D, Eardley I, Kell P, et al. Improvement in erectile function on vardenafil treatment correlates with treatment satisfaction in both patients and their partners. BJU Int 2007; 100: 130-6.
22. Rosen R, Shabsigh R, Berber M, et al. Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study. Am J Psychiatry 2006; 163: 79-87.
23. Stief C, Porst H, Saenz De Tejada I, Ulbrich E, Beneke M. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract 2004; 58: 230-9.
24. Rosen R, Goldstein I, Huang XY, Bangerter K, Taylor T. The Treatment Satisfaction Scale (TSS) is a sensitive measure of treatment effectiveness for both patients and partners: results of a randomized controlled trial with vardenafil. J Sex Med 2007; 4: 1009-21.
25. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003; 26: 777-83.
26. Donatucci C, Taylor T, Thibonnier M, Bangerter K, Gittelman M, Casey R. Vardenafil improves patient satisfaction with erection hardness, orgasmic function, and overall sexual experience, while improving quality of life in men with erectile dysfunction. J Sex Med 2004; 1: 185-92.
27. Padma-Nathan H, Montorsi F, Giuliano F, et al. Vardenafil restores erectile function to normal range in men with erectile dysfunction. J Sex Med 2007; 4: 152-61.
28. van Ahlen H, Wahle K, Kupper W, Yassin A, Reblin T, Neureither M. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med 2005; 2: 856-64.
29. World Health Organization. Men, Ageing And Health: Achieving Health Across the Life Span. Geneva, Switzerland: World Health Organization, 2001.
30. Dowson AJ, Almqvist P. Part III: the convenience of, and patient preference for, zolmitriptan orally disintegrating tablet. Curr Med Res Opin 2005; 21(Suppl 3): S13-7.
31. Hackett GI. Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education. Clin Cornerstone 2005; 7: 57-65.